Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of “Moderate Buy” by Analysts

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $28.6667.

A number of brokerages recently issued reports on KYTX. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. HC Wainwright raised their price target on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Wells Fargo & Company boosted their price objective on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Finally, Morgan Stanley set a $33.00 target price on shares of Kyverna Therapeutics in a research report on Monday, December 15th.

Insiders Place Their Bets

In other news, major shareholder Biopartners Opportuni Westlake bought 133,333 shares of the stock in a transaction dated Thursday, December 18th. The stock was bought at an average price of $7.50 per share, for a total transaction of $999,997.50. Following the purchase, the insider directly owned 869,317 shares in the company, valued at $6,519,877.50. This trade represents a 18.12% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Beth C. Seidenberg purchased 133,333 shares of Kyverna Therapeutics stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average cost of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the purchase, the director owned 869,317 shares of the company’s stock, valued at $6,519,877.50. This trade represents a 18.12% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 22.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KYTX. Bank of America Corp DE grew its holdings in Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after purchasing an additional 6,400 shares during the period. Nuveen LLC purchased a new stake in shares of Kyverna Therapeutics in the 1st quarter worth approximately $92,000. Cubist Systematic Strategies LLC increased its position in Kyverna Therapeutics by 31.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock valued at $132,000 after buying an additional 16,267 shares in the last quarter. AQR Capital Management LLC bought a new position in Kyverna Therapeutics during the 1st quarter valued at approximately $137,000. Finally, Insight Holdings Group LLC raised its stake in Kyverna Therapeutics by 8.3% during the first quarter. Insight Holdings Group LLC now owns 989,054 shares of the company’s stock valued at $1,909,000 after buying an additional 76,139 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Stock Up 9.6%

Shares of NASDAQ KYTX opened at $8.70 on Thursday. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $13.67. The firm’s fifty day moving average is $7.85 and its 200 day moving average is $5.71. The company has a market cap of $381.06 million, a price-to-earnings ratio of -2.33 and a beta of 3.45.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.12. Equities research analysts anticipate that Kyverna Therapeutics will post -3.29 earnings per share for the current year.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.